Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:13476 |
Name | supraglottis cancer |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer larynx cancer supraglottis cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
MLH1 negative | Pembrolizumab | supraglottis cancer | sensitive | detail... |
MSH6 negative | Pembrolizumab | supraglottis cancer | sensitive | detail... |
FGFR1 act mut | Erdafitinib | supraglottis cancer | sensitive | detail... |
FGFR1 fusion | Erdafitinib | supraglottis cancer | sensitive | detail... |
FGFR2 fusion | Erdafitinib | supraglottis cancer | sensitive | detail... |
FGFR3 act mut | Erdafitinib | supraglottis cancer | sensitive | detail... |
FGFR3 fusion | Erdafitinib | supraglottis cancer | sensitive | detail... |
FGFR2 act mut | Erdafitinib | supraglottis cancer | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|